Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
27 Febbraio 2025 - 3:03PM
UK Regulatory
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo
Nordisk A/S
Bagsværd, Denmark, 27 February 2025 – The
Annual General Meeting of Novo Nordisk A/S will be held on:
Thursday 27 March 2024 at 14.00 (CET)
The Annual General Meeting is held as a partially electronic
general meeting. Accordingly, shareholders can choose between
participating in person at Bella Center, Center Boulevard 5,
DK-2300 Copenhagen S, Denmark or participating virtually via an IT
application. We encourage shareholders to exercise their rights by
submitting proxies or votes by correspondence in advance of the
Annual General Meeting.
Also, Novo Nordisk offers the possibility of viewing the Annual
General Meeting via live webcast on Novo Nordisk’s website.
Please refer to the enclosed notice for the Annual General
Meeting for further information.
BOARD OF DIRECTORS
All Board members elected by the Annual General Meeting are up for
election.
The Board of Directors proposes re-election of Helge Lund as
chair of the Board and re-election of Henrik Poulsen as vice chair.
Moreover, the Board proposes re-election of the following Board
members: Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim
Kutay, Christina Law and Martin Mackay as members of the Board.
Novo Nordisk is a leading global healthcare company founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases built upon our heritage
in diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines and working to prevent and
ultimately cure disease. Novo Nordisk employs about 76,300 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram,
X, LinkedIn and
YouTube.
Contacts for further information
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
Ida
Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
|
Sina
Meyer
+45 3079 6656
azey@novonordisk.com
|
Max
Ung
+45 3077 6414
mxun@novonordisk.com
|
Frederik
Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
|
|
Company announcement No 10 / 2025
- CA250227-AGM-notice-combined
Grafico Azioni Novo Nordisk (TG:NOV)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Novo Nordisk (TG:NOV)
Storico
Da Mar 2024 a Mar 2025